Mereo BioPharma Group plc (MREO): Nasdaq/NYSE listing notice — Mereo Biopharma receives Nasdaq bid price deficiency notice; compliance period through Aug 2026

Mereo BioPharma Group plc

Received letter on Feb 17, 2026 re: ADS closing bid price below $1.00 for 30 consecutive business days.
180-day compliance period until August 17, 2026 to regain minimum bid price requirement.
To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
If not compliant by Aug 17, may be eligible for additional 180-day grace period subject to other Nasdaq standards.
ADSs continue trading under MREO; company states business operations unaffected.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Mereo BioPharma Group plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its American Depositary Shares (“ADSs”) failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notification Letter does not result in the immediate delisting of the Company’s ADSs, and the ADSs will contin

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-26-054787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.